摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 5-methoxycarbonyl-1-(β-D-ribofuranosyl)imidazole-4-carboxylate | 66657-10-1

中文名称
——
中文别名
——
英文名称
methyl 5-methoxycarbonyl-1-(β-D-ribofuranosyl)imidazole-4-carboxylate
英文别名
methyl 1-β-D-ribofuranosyl-4,5-imidazoledicarboxylate;methyl 1-β-D-ribofuranosylimidazole-4,5-dicarboxylate;1-(β-D-Ribofuranosyl)-imidazol-4,5-dicarbonsaeure-dimethylester;Dimethyl-1-β-D-ribofuranosylimidazol-4,5-dicarboxylat;1-β-D-ribofuranosyl-1H-imidazole-4,5-dicarboxylic acid dimethyl ester;dimethyl 1-β-D-ribofuranosyl-imidazole-4,5-dicarboxylate;dimethyl 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4,5-dicarboxylate
methyl 5-methoxycarbonyl-1-(β-D-ribofuranosyl)imidazole-4-carboxylate化学式
CAS
66657-10-1
化学式
C12H16N2O8
mdl
——
分子量
316.268
InChiKey
ZTQPDVCRKOIDBW-UUOKUNOPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.2
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    140
  • 氢给体数:
    3
  • 氢受体数:
    9

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    环扩增(“脂肪”)核苷和核苷酸类似物对黄病毒NTPase / Helase(包括西尼罗河病毒,丙型肝炎病毒和日本脑炎病毒)表现出强大的体外活性。
    摘要:
    一系列含有咪唑并[4,5-e] [1,3]二氮杂ring环系统的环膨胀(“脂肪”)杂环,核苷和核苷酸类似物(REN)(9、14、15、18、24-26 ,28、31和33)和咪唑并[4,5-e] [1,2,4]三氮杂ring环系统(30b,30c,32和34)已被合成为黄病毒科NTPase /螺旋酶的潜在抑制剂包括西尼罗河病毒(WNV),丙型肝炎病毒(HCV)和日本脑炎病毒(JEV)。该研究还包括人酶Suv3(delta1-159)的氨基末端截短形式,以评估RENs对病毒酶的选择性。REN的类似物包括杂环碱基第1位的结构变异,并且在两种糖部分的类型(核糖,2'-脱氧核糖,和无环糖)以及这些糖与杂环碱基的连接方式(α与β端基异构构型)。针对病毒NTPase / helase的解旋酶和ATPase活性分别进行生化筛选目标REN。许多REN抑制病毒解旋酶活性,其IC50值在微摩尔浓度范围内变化,
    DOI:
    10.1021/jm030842j
  • 作为产物:
    描述:
    methyl 2-chloro-1-(2,3-O-methoxymethylidene-5-O-tert-butyldimethylsilyl-β-D-ribofuranosyl)imidazole-4-carboxylate 在 palladium on activated charcoal 氢气溶剂黄146三乙胺lithium diisopropyl amide 作用下, 以 四氢呋喃甲醇 为溶剂, -70.0~25.0 ℃ 、303.98 kPa 条件下, 反应 4.75h, 生成 methyl 5-methoxycarbonyl-1-(β-D-ribofuranosyl)imidazole-4-carboxylate
    参考文献:
    名称:
    A lithiation route to c-5 substitution of an imidazole nucleoside and its application to the synthesis of 3-deazaguanosine
    摘要:
    DOI:
    10.1016/s0040-4020(01)87613-4
点击查看最新优质反应信息

文献信息

  • An Efficient, Short Synthesis, and Potent Anti-Hepatitis B Viral Activity of a Novel Ring-Expanded Purine Nucleoside Analogue Containing a 5:7-Fused, Planar, Aromatic, Imidazo[4,5-<i>E</i>][1,3]diazepine Ring System
    作者:Huan-Ming Chen、Ramesh Sood、Ramachandra S. Hosmane
    DOI:10.1080/15257779908043079
    日期:1999.3
    An efficient, short synthesis of a ring-expanded nucleoside analogue containing a novel 5:7-fused, planar, and potentially aromatic imidazo[4,5-e][1,3]diazepine heterocyclic ring system is reported. The target compound, 6-amino-8-hydroxy-4H-1-beta-D- ribofuranosylimidazo[4,5-e][1,3]diazepin-4-one (2) was synthesized in a single step in > or = 90% yield by condensation of guanidine with either methyl
    高效,短环合成含有新型5:7融合,平面和潜在芳香族咪唑并[4,5-e] [1,3]二氮杂杂环体系的核苷类似物的报告。目标化合物6-氨基-8-羟基-4H-1-β-D-呋喃核糖嘧啶偶氮[4,5-e] [1,3]二氮杂-4--4-(2)一步合成通过胍与1-β-D-呋喃呋喃基嘧啶甲基-4,5-二羧酸甲酯(1a)或其2',3',5'-三-O-苯甲酰基衍生物(1b)的缩合得到= 90%的收率。化合物2在转染的肝癌细胞系2.2.15中显示出有效的抗乙型肝炎病毒(anti-HBV)活性,EC50值为0.17 microM,CC50值为2.4 mM的细胞毒性低(TI> 14,000)。
  • US4115641A
    申请人:——
    公开号:US4115641A
    公开(公告)日:1978-09-19
  • Ring-Expanded (“Fat”) Nucleoside and Nucleotide Analogues Exhibit Potent in Vitro Activity against <i>Flaviviridae</i> NTPases/Helicases, Including Those of the West Nile Virus, Hepatitis C Virus, and Japanese Encephalitis Virus
    作者:Ning Zhang、Huan-Ming Chen、Verena Koch、Herbert Schmitz、Ching-Len Liao、Maria Bretner、Vishweshwar S. Bhadti、Ali I. Fattom、Robert B. Naso、Ramachandra S. Hosmane、Peter Borowski
    DOI:10.1021/jm030842j
    日期:2003.9.1
    A series of ring-expanded ("fat") heterocycles, nucleoside and nucleotide analogues (RENs) containing the imidazo[4,5-e][1,3]diazepine ring system (9, 14, 15, 18, 24-26, 28, 31, and 33) and imidazo[4,5-e][1,2,4]triazepine ring systems (30b, 30c, 32, and 34), have been synthesized as potential inhibitors of NTPases/helicases of Flaviviridae, including the West Nile virus (WNV), hepatitis C virus (HCV)
    一系列含有咪唑并[4,5-e] [1,3]二氮杂ring环系统的环膨胀(“脂肪”)杂环,核苷和核苷酸类似物(REN)(9、14、15、18、24-26 ,28、31和33)和咪唑并[4,5-e] [1,2,4]三氮杂ring环系统(30b,30c,32和34)已被合成为黄病毒科NTPase /螺旋酶的潜在抑制剂包括西尼罗河病毒(WNV),丙型肝炎病毒(HCV)和日本脑炎病毒(JEV)。该研究还包括人酶Suv3(delta1-159)的氨基末端截短形式,以评估RENs对病毒酶的选择性。REN的类似物包括杂环碱基第1位的结构变异,并且在两种糖部分的类型(核糖,2'-脱氧核糖,和无环糖)以及这些糖与杂环碱基的连接方式(α与β端基异构构型)。针对病毒NTPase / helase的解旋酶和ATPase活性分别进行生化筛选目标REN。许多REN抑制病毒解旋酶活性,其IC50值在微摩尔浓度范围内变化,
  • A lithiation route to c-5 substitution of an imidazole nucleoside and its application to the synthesis of 3-deazaguanosine
    作者:Hiromichi Tanaka、Masashi Hirayama、Masahiro Suzuki、Tadashi Miyasaka、Akira Matsuda、Tohru Ueda
    DOI:10.1016/s0040-4020(01)87613-4
    日期:1986.1
查看更多

同类化合物

阿卡地新 咪唑立宾 5'-单磷酸酯 咪唑立宾 [(2R,3S,4R,5R)-5-[4-氨基甲酰-5-[[(3R,4R)-3,4-二羟基-2-氧代-5-膦酰氧基戊基]亚氨基甲基氨基]咪唑-1-基]-3,4-二羟基四氢呋喃-2-基]磷酸二氢甲酯 N-[5-氨基-1-(BETA-D-呋喃核糖基)咪唑-4-羰基]-L-天冬氨酸 5-碘-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)-咪唑并-4-甲腈 5-甲酰氨基咪唑-4-甲酰胺核苷酸 5-氯-1-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]咪唑-4-甲酰胺 5-氨基-4-咪唑甲酰胺核糖甙 5'-三磷酸酯 5-氨基-1-(2-O,3-O,5-O-三乙酰基-beta-D-呋喃核糖基)-1H-咪唑-4-甲酰胺 5-氨基-1-(2,7-二羟基-2-氧代四氢-4H-呋喃并[3,2-d][1,3,2]二氧杂环己膦烷-6-基)-1H-咪唑-4-甲酰胺 5-乙炔基-1-呋喃核糖基咪唑-4-甲酰胺 4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑 2-硝基-1-beta-D-呋喃核糖基-1H-咪唑 1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 1-(alpha-D-阿拉伯呋喃糖基)-1H-咪唑-2-胺 (2S)-2-[[5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(膦酰氧基甲基)四氢呋喃-2-基]咪唑-4-羰基]氨基]丁二酸 (2R)-2-环己基-2-羟基-2-苯基乙酸 (1-羟基乙基)-5-甲基-1-beta-呋喃核糖基咪唑 5-amino-1-(β-D-ribofuranosyl)-4-(5-propyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-phenyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-ethyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-[1-(Dimethylamino)ethylideneamino]-1-[2,3-O-(1-methylethylidene)-β-D-ribofuranosyl]-imidazole-4-carbonitrile 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-4-(3-ureidophenyl)imidazole 5-amino-2-(4-fluorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(3-chlorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(4-methoxyphenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-phenylvinyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-phenyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-furyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-2-(2-thienyl)-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamideoxime hydrochloride acadesine-5’-O-bis(benzoxy-L-alaninyl)phosphate 5-diazonium-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide 5-amino-1-(3-O-methyl-β-D-ribofuranosyl)imidazole-4-carboxamide 5-amino-1-(3-O-n-butyl-β-D-ribofuranosyl) imidazole-4-carboxamide 5-amino-1-(3-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide 5-amino-1-(2-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide N4-(benzyl) AICAR triphosphate N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleotide N1-<(5''-Phospho-β-D-ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside 2-Benzyl-1-(β-D-ribofuranosyl)imidazol-4,5-dicarboxamid 4-N-[(S)-pyrrolidine-2-carbonyl]amino-1-β-D-ribofuranosylimidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-pentyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-heptyl-1,2,4-oxadiazol-3-yl)imidazole acadesine-5’-O-bis(methoxy-L-alaninyl)phosphate 4,5-dichloro-1-(β-D-ribofuranosyl)imidazole